Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | MARS1 | P56192 | 7/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721686 | 1.00 | HCAR2 (0.43) | HCAR2KIF11MARS1CTSCFNTA | |
| SCHEMBL11340217 | 0.87 | KIF11 (0.56) | KIF11MARS1CTSCFNTAFNTB | |
| SCHEMBL28493116 | 0.80 | HCAR2 (0.49) | HCAR2KIF11CYP1A2CYP2D6PKM | |
| SCHEMBL28268220 | 0.79 | HCAR2 (0.47) | HCAR2KIF11CYP1A2CYP2D6PKM | |
| SCHEMBL7944346 | 0.79 | HCAR2 (0.47) | HCAR2KIF11MMEANPEPCYP1A2 | |
| SCHEMBL20121831 | 0.79 | ALDH1A1 (0.48) | HCAR2SMN1; SMN2 | |
| SCHEMBL28265844 | 0.78 | ALPI (0.54) | HCAR2ANPEPPKMFFAR1 | |
| SCHEMBL7546444 | 0.78 | ATM (0.43) | MARS1CTSCMMEANPEP | |
| SCHEMBL7781980 | 0.78 | ATM (0.43) | MARS1CTSCMMEANPEP | |
| SCHEMBL24251134 | 0.77 | HCAR2 (0.45) | HCAR2CYP1A2CYP2D6FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | PNP, SAMHD1, MTAP | HCAR2 4495/4885KIF11 3646/4885MARS1 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.